XNASHRMY
Market cap1.93bUSD
Jan 10, Last price
33.86USD
1D
-1.94%
1Q
-2.78%
IPO
-6.20%
Name
Harmony Biosciences Holdings Inc
Chart & Performance
P/E
14.99
P/S
3.32
EPS
2.26
Div Yield, %
0.00%
Shrs. gr., 5y
4.16%
Rev. gr., 5y
%
Revenues
582m
+32.93%
Net income
129m
-28.99%
CFO
219m
+51.86%
Earnings
Feb 20, 2025
Profile
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
IPO date
Aug 19, 2020
Employees
200
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 582,022 32.93% | 437,855 43.35% | ||||
Cost of revenue | 389,992 | 317,669 | ||||
Unusual Expense (Income) | ||||||
NOPBT | 192,030 | 120,186 | ||||
NOPBT Margin | 32.99% | 27.45% | ||||
Operating Taxes | 44,543 | (76,782) | ||||
Tax Rate | 23.20% | |||||
NOPAT | 147,487 | 196,968 | ||||
Net income | 128,853 -28.99% | 181,468 424.52% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (100,000) | 8,841 | ||||
BB yield | 5.13% | -0.26% | ||||
| Debt | ||||||
Debt current | 15,000 | 2,000 | ||||
Long-term debt | 179,648 | 190,622 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 2,109 | 2,501 | ||||
Net debt | (230,981) | (153,061) | ||||
| Cash flow | ||||||
Cash from operating activities | 219,387 | 144,466 | ||||
CAPEX | (312) | (40,172) | ||||
Cash from investing activities | (46,439) | (141,832) | ||||
Cash from financing activities | (105,552) | 6,841 | ||||
FCF | 147,689 | 197,215 | ||||
| Balance | ||||||
Cash | 353,460 | 323,115 | ||||
Long term investments | 72,169 | 22,568 | ||||
Excess cash | 396,528 | 323,790 | ||||
Stockholders' equity | (143,274) | (272,280) | ||||
Invested Capital | 805,941 | 869,266 | ||||
ROIC | 17.61% | 23.11% | ||||
ROCE | 28.98% | 20.13% | ||||
| EV | ||||||
Common stock shares outstanding | 60,372 | 61,097 | ||||
Price | 32.30 -41.38% | 55.10 29.22% | ||||
Market cap | 1,950,028 -42.07% | 3,366,447 33.35% | ||||
EV | 1,719,047 | 3,213,386 | ||||
EBITDA | 216,389 | 143,571 | ||||
EV/EBITDA | 7.94 | 22.38 | ||||
Interest | 23,757 | 15,669 | ||||
Interest/NOPBT | 12.37% | 13.04% | ||||